11 November 2022 - - US-based healthcare technology and diagnostics company binx health has inked a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization, the company said.

Under the agreement, binx will offer its FDA-cleared, CLIA-waived point-of-care test for chlamydia and gonorrhea and its at-home digital health platform to thousands of clinics across the United States, under a preferred pricing model with joint marketing outreach among Afaxys and binx.

binx currently collaborates with Afaxys and their GPO members, including leading universities, community health clinics, and state departments of public health to expand access to STI testing with its omnichannel platform that extends from clinic to home--the only company of its kind reaching patients in the locations and in the ways most convenient for them (in clinic, at home, in dorm, in retail settings, etc.).

The binx io is the first and only FDA-Cleared, CLIA-Waived platform that can deliver rapid, central-lab quality diagnostic testing results for CT and NG for both males and females in about 30 minutes. 

binx everywhere is a physician-mediated digital platform and logistics solution that enables a patient to conveniently self-collect a sample discreetly for analysis from a network of partner laboratories and clinical follow-up if necessary.

binx everywhere supports a variety of STI panels, including HIV, and provides capabilities to support pre-exposure prophylaxis medication protocols.

Recent Centers for Disease Control and Prevention statistics indicate that in the United States between 2014 and 2018 chlamydia cases increased by 19% and gonorrhea cases by 63%.

If left undetected and untreated, these diseases can result in serious and irreversible health consequences, including infertility.

CDC officials recently issued a national call to action to reduce the stigma surrounding STIs, broaden screening and treatment services, and support the accessibility of self-sample collection kits for STIs.

The CDC has declared STIs a public health epidemic4 and recommends routine testing for chlamydia and gonorrhea for all women ages 15-24, including at-risk pregnant women.

Planned Parenthood alone administered more than 4.45m STI tests and treatments in 2020 and 2021, accounting for more than half of its total healthcare service delivery.

Together, binx and Afaxys GPO members, including public health departments and community health centers, all play critical roles in STI prevention, diagnosis, and treatment by reaching ms of people at risk, particularly women in underserved communities.

binx is a healthcare technology and diagnostics company that is leading the way to accessible routine testing by partnering with primary care, public health, retail health, universities, and leaders in HIV prevention and sexual health to reach underserved populations and impede the spread of infection.

The company's omnichannel platform is the only healthcare delivery model designed to reach people in-clinic and at-home with novel access modalities focused on the patient. binx is paving the way to improve population health issues at scale in partnership with those on the front lines of care.

The company's dual-care offerings include the binx io, the first ever FDA-cleared, CLIA-waived, point-of-care chlamydia and gonorrhea test for males and females providing central lab performance results in about thirty minutes, and binx everywhere, a physician-mediated, secure, and highly configurable technology platform that integrates self-collection with high-quality laboratory testing and follow-up.

binx's proprietary platforms enable organizations to broaden access to care, promote health equity, and connect all key stakeholders of healthcare delivery in a seamless, evidenced-based manner that engenders consumer delight.

binx everywhere may not be available in all geographies outside of the US.